Asthma drug mix-up may pose safety risk
A pharma maker is recalling one lot of an allergy medication because the bottles mistakenly contain this medication.
A pharma maker is recalling one lot of an allergy medication because the bottles mistakenly contain a high blood pressure medication.
Camber Pharmaceuticals is voluntarily recalling the lot of 10 mg, 30-count bottles of Montelukast Sodium tablets, which actually contain 90 tablets of Losartan Potassium Tablets, 50 mg.
Related: Cancer risk found with common blood pressure med
“This tablet mix-up may pose a safety risk as taking losartan tablets when not prescribed has the potential to cause renal dysfunction, elevated potassium levels and low blood pressure,” FDA said in a statement.
The risk is especially high for pregnant women taking the allergy and asthma medication montelukast because losartan, used to treat high blood pressure, could harm or kill the fetus.
“We want to ensure that patients who take montelukast are aware of this recall due to the serious risks associated with taking losartan in its place,” said Donald D. Ashley, director of the office of compliance in the FDA’s center for drug evaluation and research, in the FDA statement. “Patients who take prescription drugs expect and deserve to have the medication their doctor prescribed.”
Related: Top 3 drug alerts of 2018
FDA recommends that consumers with the recalled product should contact their healthcare provider or pharmacist immediately.
The recall is not related to the recent valsartan recalls that were due to an impurity, N-nitrosodimethylamine (NDMA).
Recalled montelukast sodium tablets include the lot number: MON17384, and expiration date 12/31/2019.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
